key: cord-0862046-kazspce8 authors: Yao, Xiaolong; Liu, Shengwen; Wang, Junwen; Zhao, Kai; Long, Xiaobing; He, Xuejun; Kang, Huicong; Yang, Yiping; Ma, Xiaopeng; Yue, Pengjie; Shu, Kai; Tang, Zhouping; Lei, Ting; Liu, Jihong; Wang, Wei; Zhang, Huaqiu title: The clinical characteristics and prognosis of COVID‐19 patients with cerebral stroke：a retrospective study of 113 cases from one single center date: 2020-10-14 journal: Eur J Neurosci DOI: 10.1111/ejn.15007 sha: eadea96be0356d813f8e81660db915896dd5dab7 doc_id: 862046 cord_uid: kazspce8 To explore the clinical characteristics and prognosis of COVID‐19 patients with cerebral stroke. A total of 2474 COVID‐19 patients from February 10th to March 24th, 2020 were admitted and treated in two branches (Optic Valley and Sino‐French New City branch) of the Tongji Hospital. Data on the clinical characteristics, laboratory parameters and prognosis of COVID‐19 patients with or without cerebral stroke were collected and comparatively analysed. Of the 2474 COVID‐19 patients, 113 (4.7%) patients had cerebral stroke, and 25 (1.0%) patients had new‐onset stroke. Eighty‐eight (77.9%) patients in the previous‐stroke group had cerebral ischaemia, while 25 (22.1%) patients in the new‐onset stroke group had cerebral ischaemia. Most COVID‐19 patients with stroke were elderly with more comorbidities, such as hypertension, diabetes and heart diseases than patients without stroke. Laboratory examinations showed hypercoagulation and elevated serum parameters such as IL‐6, cTnI, NT pro‐BNP and BUN. Consciousness disorders, a long disease course and poor prognosis were also more commonly observed in stroke patients. The mortality rate of stroke patients was almost double (12.4% vs 6.9%) that of patients without stroke. In addition, age, male sex and hypertension were independent predictors for new cerebral stroke in COVID‐19 patients. In conclusion, the high risk of new‐onset stroke must be taken into consideration when treating COVID‐19 patients with an elderly age combined with a history of hypertension. These patients are more vulnerable to multiorgan dysfunction and an overactivated inflammatory response, in turn leading to an unfavourable outcome and higher mortality rate. In late December 2019, viral pneumonia caused by severe acute respiratory syndrome Stroke, also known as an acute cerebrovascular disease, has various vascular causes (including ischaemic and haemorrhagic stroke) with neurological dysfunction. COVID-19 patients with stroke can present with disturbance of consciousness and difficulties performing physical activity, which may result in central respiratory depression and exacerbate the lung infection 2 . On the other hand, severe COVID-19 cases are often accompanied by hypoxia, impaired cardiac function and abnormal blood coagulation, which are high-risk factors for stroke [3] [4] [5] . Considering the different clinical characteristics and prognosis of ischaemic and haemorrhagic stroke and the elevated incidence of ischaemic stroke, we explored the interacting effects between ischaemic stroke and SARS-CoV-2 infection; this information will be of great benefit to better prevent and treat stroke-related clinical symptoms in COVID-19 patients. In the present study, we separately reported the clinical characteristics and prognosis of COVID-19 patients with previous or new-onset stroke. The risk factors for new-onset stroke were also investigated. Our study revealed the effects of cerebral stroke on the clinical features and prognosis of COVID-19 patients and provided novel insights into the spectrum of this disease. We hope our study may provide a reference to improve the treatment of COVID-19 patients with stroke. This article is protected by copyright. All rights reserved The clinical data, including basic information (age and sex), past medical history (hypertension, diabetes, heart disease and others), typical symptoms (fever, cough, shortness of breath, muscle ache and diarrhoea), neurological symptoms (headache, dizziness and consciousness disorders), medical course, laboratory findings (blood cell count, serum inflammation factors, serum biochemical analysis data, serum electrolytes and blood coagulation factors), chest and brain computed tomography (CT) scans, treatment and outcomes, were retrospectively collected by carefully reviewing the medical records of patients with laboratory-confirmed SARS-CoV-2 infection. Symptoms were assessed by direct communication with conscious patients or with relatives of unconscious persons. Additionally, consciousness disorders were exclusively evaluated by experienced neurologists. Laboratory examinations were performed on admission and when necessary in our hospital. The highest value of each laboratory parameter for the patients during hospitalization was collected for statistical analysis. We defined a composite end point as the date of patient discharge, death or March 24 th , 2020. Accordingly, we evaluated two medical courses for each patient, including days from onset to the end of observation as Accepted Article well as days from hospital admission to the end of observation. Stroke is a severe cerebrovascular disease and is divided into two types: cerebral ischaemic infarction and cerebral haemorrhage [4] [5] . In the present study, we enrolled all patients with only ischaemic infarction. In accordance with the period of stroke occurrence, we further categorized COVID-19 patients with stroke into two groups. One was the previous-stroke group, in which the patients had a stroke at least one month prior to the confirmation of COVID-19. The other group was the new-stroke group, in which a stroke occurred after the COVID-19 diagnosis. The occurrence of a previous stroke was identified from personal medical records. New strokes in COVID-19 patients were identified by brain CT or MRI. The diagnosis of stroke was carefully confirmed by at least two trained neurologists. All patients received personal systematic treatments in accordance with the WHO interim guidelines 3 , including antiviral therapy, oxygen support, secondary infection control, multiorgan monitoring and support and so on. Oxygen support was one of the most important approaches and was consistently provided through normal or high-flow nasal cannulas, non-invasive ventilation, invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO) 2 . For patients with ischaemic stroke, anti-coagulation, high brain perfusion and brain protection therapy were administered. To treat patients with haemorrhagic stroke, haemostatic drugs, control of brain oedema and swelling and brain protective agents were applied 6 . In our patient series, none of the stroke patients underwent neurosurgical interventions. In light of the end point of observation, the outcomes of COVID-19 patients included discharge, hospitalization and death. All statistical analyses were performed using SPSS 17.0 statistical software. For continuous data, the mean ± standard deviation (SD) and median with range are reported for normal and abnormal distribution data, respectively. One-way ANOVA was used to analyse the variance of multiple groups. Student's t-test was used to compare data with a normal This article is protected by copyright. All rights reserved distribution between the two groups, and nonparametric analysis and the Mann-Whitney U test was used to compare data with a non-normal distribution between the two groups. Qualitative data are expressed as counts and percentages, and the chi-square test was used for comparisons. The significant predictors in the univariate analysis were included in multivariate analysis, and the enter method was applied for multivariate regression analysis to determine the risk factors for new-onset stroke in COVID-19 patients. The distribution of overall survival of each group was estimated by using the Kaplan-Meier method and compared by using the log-rank test. P < 0.05 was statistically significant. The essential clinical information of COVID-19 patients is summarized in Table 1 . A total of 2474 patients were included in this study, with a mean age of 61.0±15.7 years. The mean age of patients in the stroke group was significantly older than that of the patients in the non-stroke group (P< .001). Specifically, patients older than 60 years were more frequently observed in the stroke group than in the non-stroke group (P<.001). However, there was no difference in sex between groups (P=.558). Comorbidities (hypertension, diabetes and heart disease) were more common among patients with stroke (all P<.001). Moreover, the stroke patients showed a higher incidence of consciousness disorders than non-stroke patients (P<.001), while the other common symptoms, such as cough, shortness of breath, and diarrhoea, were similar. Stroke patients were more likely to have low fingertip oxygen saturation than non-stroke patients (P<.001). The stroke patients were further divided into two subgroups according to the time point of stroke onset: patients with previous stroke and patients with new stroke. The detailed clinical characteristics of the patients in different subgroups are listed in Table 1 . Generally, there were 88 patients with previous stroke and 25 patients with newly identified stroke. In comparison to non-stroke patients, both previous-and new-stroke patients showed similar incidences of common symptoms, such as cough, shortness of breath, diarrhoea and fever, but a higher incidence of consciousness disorders (all P<.001). The proportion of patients with headache or dizziness (44.4% vs 18.0%, P=.01) was higher among new-stroke patients than among non-stroke patients. Previous-stroke patients were more likely to have low fingertip oxygen saturation (<93%) than non-stroke patients (23.1% vs 11.5%, P<.001). This article is protected by copyright. All rights reserved and anaemia (25% and 28% vs 8.5%, P<.001, respectively) than the non-stroke group. In terms of coagulation-related indexes, significantly increased D-dimer (80.5% and 84% vs 58.8%, P<.001, respectively) and fibrinogen (Fgb, 75.6% and 80.8% vs 60.6%, P=.005 and P=.001) levels were more prevalent in previous-and new-stroke patients than in non-stroke patients. Additionally, a prolonged activated partial thromboplastin time (APTT, 47.7% vs 33.8%, P=.008), more fibrinogen degradation products (FDP, 58.9% vs 32.6%, P<.001) and higher incidence of decreased prothrombin activity (PTA, 1.1% vs 11.6%, P<.001) and thrombocytopenia (39.8% vs 19.4%, P<.001) were more prevalent among previous-stroke patients than in non-stroke patients. This article is protected by copyright. All rights reserved The stroke patients had a significantly worse outcome than the patients in the non-stroke group (P<.001), including a higher mortality rate and longer disease course. Furthermore, the mean duration from symptom onset to the end of observation was longer in the stroke group than in the non-stroke group (P<.05) (Table 1) . However, the mean duration from admission to the end of observation between the two groups was similar (Table 1) . Kaplan-Meier survival curves showed an improved overall survival (OS) for patients without stroke compared to those with previous stroke and new stroke (all P<.001) (Figure 1 ). However, no significant difference in OS was observed between patients with previous stroke and those with new stroke (Figure 1 ). Data on the clinical variables and log-rank regression analysis are listed in Table 3 . In the analysis, age≥60 years, male sex and hypertension were independent predictors for new stroke occurrence in COVID-19 patients (P=.01, P=.01 and P<.001, respectively). However, heart disease and diabetes were not independent predictors for new stroke occurrence during SARS-CoV-2 infection. In the present study, we retrospectively analysed the effect of cerebral stroke on the clinical features and prognosis of COVID-19 patients, providing novel insights into the spectrum of this disease. The prevalence of stroke (4.7%) in COVID-19 patients was markedly higher than that in the population (2.41%) without infection 7 . One possible reason is that this cohort was predominantly from the designated hospital for severely and critically ill patients. Additionally, SARS-CoV-2 infection might also promote cerebral strokes since a certain portion of cases were new onset. If this is Accepted Article the case, treating patients with viral infection and concurrent stroke will be a great burden for the public health system. COVID-19 patients share some common characteristics with the normal population in terms of risk factors for stroke, including older age 8 , and stroke patients had more comorbidities 9 , such as hypertension, diabetes and heart disease. However, only hypertension was an independent predictor for new stroke in this study. As the robustly increased levels of biomarkers (e.g., cTnI, CK-MB, NT pro-BNP, Cr, BUN and IL-6) predicts extrapulmonary organ injuries, the presence of multiorgan dysfunction and overactivated systematic inflammation were more common in COVID-19 patients with stroke than in those without stroke. These changes are important factors contributing to the unfavourable outcomes of patients with stroke and were also widely observed in patients with severe disease 10-14 and deceased patients 1 . In addition, due to dysphagia, impaired locomotor function and insufficient nutrition 15 , patients with stroke have poor immunity and cardiac function, leading to a huge risk for suffering from hospital-acquired pneumonia caused by organisms other than viruses [16] [17] . This is especially critical for stroke patients who lose consciousness and spontaneous respiration, thus requiring mechanical ventilation 18 . Coinfection will in turn aggravate the illness in COVID-19 patients 1, 19 . In this study, the higher incidence of consciousness disorders in stroke patients might be an early sign related to their poor outcomes. Cytokine storms are widely considered to be a factor leading to the aggravation of pneumonia and extrapulmonary injuries such as cardiac and renal failure [12] [13] . There might be a correlation between cytokines and stroke. Associated with cerebrovascular risks, increases in cytokines and systemic inflammation-related factors such as IL-6, C-reactive protein and monocyte chemotactic protein 1 in acute respiratory tract infections were triggers for stroke [23] [24] . Since inflammatory responses mediated by cytokines were found to disturb the stability of coronary plaque, which leads to cardiac ischaemia 25 , we speculate that cytokines might also affect the stability of carotid and cerebrovascular atherosclerosis, resulting in abnormal occlusive thrombus or the rupture of blood vessels. The markedly elevated levels of IL-6 in new-stroke patients in this study could help to support this hypothesis. However, the other cytokines were not found to differ between stroke and non-stroke patients. In addition, viral infection of the vascular endothelium is another possible mechanism. SARS-CoV-2 is highly homologous in the genome of SARS-CoV 2 and may also have high affinity for the host angiotensin-converting enzyme 2 receptor 20,26 . This mechanism needs further investigation even though vasculitis caused by viral infection is a risk factor for stroke 26 . Additionally, in the new-onset stroke group, the incidence of haemorrhagic stroke was markedly increased in comparison with that in the previous-stroke group. This might be related to impaired blood coagulation, so the administration of haemostatic drugs should be rigorously considered. As mentioned above, COVID-19 patients with stroke were more vulnerable to multiorgan dysfunction and an overactivated inflammatory response, which in turn resulted in significantly impaired outcomes. In this study, patients with stroke had a nearly double the mortality rate of patients without stroke. The discharge rate of patients with stroke was only half of that of patients without stroke. In comparison This article is protected by copyright. All rights reserved to patients without stroke, not only patients with previous stroke but also those with new stroke had a significantly decreased OS. Our study has a few limitations. First, because the outbreak of SARS-CoV-2 occurred in a short time and the public health resources were seriously restricted, some patients could not be hospitalized in time, leading to a deviation between the observation point of the disease course and the length of stay in the hospital. This also results in the absence of initial values of laboratory parameters at symptom onset. Second, some tests (for example, cTnI, NT pro-BNP, and arterial blood gas tests) were not performed in all patients, and missing data might lead to bias in the analysis of clinical characteristics. Additionally, considering that this is a single-centre retrospective study that only enrolled severe and critically ill COVID-19 patients, mild or asymptomatic COVID-19 patients were excluded, and further studies are warranted to gain a better understanding of the risk factors for and outcomes of COVID-19 patients combined with stroke. To summarize, elderly COVID-19 patients with hypertension are more likely to develop cerebral stroke, which is associated with severe neurological symptoms, multiorgan injuries, coagulation dysfunction and an overactivated inflammatory response. All these factors will contribute to unfavourable outcomes, including a prolonged disease course, shortened OS and high mortality. Therefore, intensive treatments for both COVID-19 and stroke must be taken into consideration for patients with risk factors for stroke. This article is protected by copyright. All rights reserved This article is protected by copyright. All rights reserved This article is protected by copyright. All rights reserved Neurologic Manifestations of Hospitalized Patients with Coronavirus Disease Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19 Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected, Interim guidance Incidence, and Mortality of Stroke in China: Results from a Nationwide Population-Based Survey of 480 687 Adults Rapid transitions in the epidemiology of stroke and its risk factors in China from Chinese guidelines for diagnosis and treatment of acute ischemic stroke Stroke in China: advances and challenges in epidemiology, prevention, and management Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study Accepted Article This article is protected by copyright. All rights reserved Clinical Characteristics of Coronavirus Disease 2019 in China Dysregulation of immune response in patients with COVID-19 in Wuhan, China Clinical and immunologic features in severe and moderate Coronavirus Disease Dysphagia screening decreases pneumonia in acute stroke patients admitted to the stroke intensive care unit Nosocomial pneumonia after acute stroke: implications for neurological intensive care medicine Risk factors of stroke-associated pneumonia in Chinese patients Risk Factors for Stroke Associated Pneumonia. Open Access Maced Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study A Novel Coronavirus from Patients with Pneumonia in China Large artery ischaemic stroke in severe acute respiratory syndrome (SARS) Impact of the 2015 Middle East Respiratory Syndrome Outbreak on Emergency Care Utilization and Mortality in South Korea Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways Common infections and the risk of stroke Ischaemic stroke in young adults: risk factors and long-term consequences Acute pneumonia and the cardiovascular system SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS Infection-related vasculitis Infections causing stroke or stroke-like syndromes WBC: white blood cell count; Hgb: hemoglobin; IL: interleukin; TNF: tumor necrosis factor; hs-CRP: hypersensitive c-reactive protein; cTnI: cardiac troponin I; MG: myohemoglobin; CK-MB: creatine kinase-mb isoenzymes; NT pro-BNP: N terminal pro-brain natriuretic peptide; BUN: blood urea nitrogen; Cr: creatinine; ALT: alanine aminotransferase; AST: aspartate aminotransferase; TT: thrombin time This article is protected by copyright. All rights reserved This article is protected by copyright. All rights reserved This article is protected by copyright. All rights reserved This article is protected by copyright. All rights reserved This article is protected by copyright. All rights reserved